About Ironwood pharmaceuticals
Ironwood Pharmaceuticals: Revolutionizing the Treatment of Gastrointestinal Diseases
Ironwood Pharmaceuticals is a healthcare company that has been making a difference in the lives of people living with gastrointestinal (GI) diseases. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Ironwood's mission is to develop innovative treatments for GI diseases that are safe, effective, and accessible to patients worldwide.
The company's focus on GI diseases stems from the fact that these conditions affect millions of people worldwide and can have a significant impact on their quality of life. Ironwood believes that by developing new treatments for these conditions, it can help improve the lives of patients and their families.
Ironwood has developed several products over the years that have been approved by regulatory agencies such as the US Food and Drug Administration (FDA). One such product is Linzess® (linaclotide), which is used to treat adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linzess® works by increasing fluid secretion in the intestines, which helps to soften stools and make them easier to pass.
Another product developed by Ironwood is Zurampic® (lesinurad), which is used in combination with other medications to treat gout. Gout is a type of arthritis caused by an excess buildup of uric acid crystals in joints. Zurampic® works by blocking a protein called URAT1, which helps reduce uric acid levels in the body.
In addition to developing new treatments for GI diseases, Ironwood also collaborates with other companies and organizations to advance research into these conditions. For example, Ironwood has partnered with Allergan plc on several projects related to gastrointestinal disorders.
One area where Ironwood has made significant progress recently is in developing treatments for refractory gastroesophageal reflux disease (GERD). GERD occurs when stomach acid flows back into the esophagus, causing symptoms such as heartburn and regurgitation. While many people can manage their symptoms through lifestyle changes or medication, some individuals experience persistent symptoms despite treatment – this condition known as refractory GERD.
Ironwood's lead candidate for refractory GERD treatment is IW-3718 – an oral formulation designed specifically for this indication. IW-3718 works by inhibiting gastric acid secretion while also providing mucosal protection against damage from stomach acid exposure.
Overall, Ironwood Pharmaceuticals continues its commitment towards improving patient outcomes through innovative research & development efforts focused on addressing unmet needs within gastrointestinal disorders space globally while collaborating closely across industry stakeholders including physicians & advocacy groups alike!
ironwoodpharma.com
